Core Viewpoint - Federal Pharmaceutical's innovative drug UBT251 has shown significant weight loss results in its Phase II clinical trial for overweight/obese patients in China, supporting its advancement to Phase III trials [2][5]. Group 1: Clinical Trial Results - UBT251 injection demonstrated a maximum average weight loss of -19.7% (-17.5 kg) after 24 weeks in the treatment group, compared to -2.0% (-1.6 kg) in the placebo group [2][5]. - Improvements in key secondary endpoints such as waist circumference, blood sugar, blood pressure, and blood lipids were significantly better in the UBT251 groups compared to the placebo [2][5]. Group 2: Safety and Tolerability - The overall safety and tolerability of UBT251 were good, with no withdrawals due to adverse events reported [2][5]. - Adverse events were similar to those of comparable drugs, primarily gastrointestinal reactions, with the majority being mild to moderate, and no unexpected safety issues were observed [2][5]. Group 3: Future Developments - The successful completion of the Phase II trial supports the initiation of the Phase III clinical study for UBT251 in overweight/obese patients in China [2][5].
联邦制药高开逾3% UBT251注射液在超重/肥胖患者中的II期临床研究达到预期目标